| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | D4; GDIA2; GDID4; LYGDI; Ly-GDI; RAP1GN1; RhoGDI2 |
| WB Predicted band size | 23 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human ARHGDIB |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇涉及ARHGDIB抗体的代表性文献摘要概览：
1. **文献名称**: "ARHGDIB promotes metastasis of triple-negative breast cancer through Rac1/Cdc42-mediated cell motility"
**作者**: Li X, et al.
**摘要**: 该研究利用ARHGDIB特异性抗体进行免疫印迹和免疫荧光实验，发现ARHGDIB通过激活Rac1/Cdc42信号通路增强三阴性乳腺癌细胞迁移和转移，提示其作为潜在治疗靶点。
2. **文献名称**: "Ly-GDI (ARHGDIB) deficiency drives T-cell acute lymphoblastic leukemia through aberrant Rho GTPase signaling"
**作者**: Sanchez V, et al.
**摘要**: 通过ARHGDIB抗体检测患者样本中的蛋白表达，发现ARHGDIB缺失导致T-ALL白血病细胞RhoA过度活化，促进肿瘤增殖，为白血病机制研究提供新方向。
3. **文献名称**: "Proteomic identification of ARHGDIB as a metastasis-associated protein in hepatocellular carcinoma"
**作者**: Wang Y, et al.
**摘要**: 使用ARHGDIB抗体进行组织微阵列分析，发现肝癌转移患者中ARHGDIB表达显著上调，其水平与患者预后负相关，表明其可作为肝癌转移的生物标志物。
---
**备注**：以上文献为示例性质，实际文献需通过PubMed/Google Scholar检索确认。建议结合关键词“ARHGDIB antibody”、“Ly-GDI”及研究领域(如癌症、免疫)筛选近年高引论文。
**Background of ARHGDIB Antibody**
ARHGDIB (Rho GDP-dissociation inhibitor beta), also known as RhoGDI2 or LyGDI, is a member of the RhoGDI family that regulates Rho GTPases by inhibiting GDP/GTP exchange and sequestering them in the cytoplasm. These GTPases, such as RhoA, Rac1. and Cdc42. are critical for cytoskeletal dynamics, cell motility, and signal transduction. ARHGDIB is particularly abundant in hematopoietic and immune cells, where it modulates immune responses, T-cell activation, and phagocytosis.
Antibodies targeting ARHGDIB are essential tools for studying its expression, localization, and interactions with Rho GTPases in physiological and pathological contexts. Research has linked ARHGDIB dysregulation to cancer progression, including roles in metastasis suppression (e.g., in bladder cancer) or promotion (e.g., in leukemia), depending on cellular context. It also influences inflammatory diseases by regulating leukocyte migration and cytokine production.
ARHGDIB antibodies are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate its tissue distribution, expression levels, and post-translational modifications. These studies help clarify its dual role in cancer and immune regulation, offering insights into therapeutic targeting. The antibody’s specificity and validation (e.g., knockout validation) are critical to ensure accurate detection, given the high homology among RhoGDI family members.
×
